The Global Cancer Therapy Market is expected to Grow at a CAGR of 9.12% by 2030, estimates DelveInsight

Cancer therapy companies are GSK, Eli Lilly, Roche, AbbVie, Amgen, Sanofi, Merck, Novartis, Pfizer, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, etc

ALBANY, NY, UNITED STATES, January 20, 2025 /EINPresswire.com/ -- DelveInsight’s Cancer Therapy Market Insights report provides the current and forecast market analysis, forthcoming therapies, individual leading cancer therapy companies’ market shares, challenges, cancer therapy market drivers, barriers, and trends, and key cancer therapy companies in the market.
The global cancer therapy market is expected to grow significantly due to the rising prevalence of cancers such as lung, colorectal, and other cancers, a growing geriatric population base, and technological advancements in sequencing that are fueling the popularity of personalized/precision medicine.

Request for sample report @ Cancer Therapy Market Forecast

Key Takeaways from the Cancer Therapy Market Report
• As per DelveInsight estimates, North America is anticipated to dominate the global cancer therapy market during the forecast period.
• Some of the leading cancer therapy companies with various new cancer therapy include GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., and others.
• Global cancer therapy market was valued at USD 169.39 billion in 2023, growing at a CAGR of 9.12% during the forecast period from 2024 to 2030, in order to reach USD 285.96 billion by 2030.
• On October 27, 2022, Imjudo (tremelimumab) from AstraZeneca was approved by the FDA in combination with Imfinzi (durvalumab) for treating unresectable liver cancer.
• On October 27, 2022, Clovis Oncology, Inc. announced the presentation of data from the TRITON3 Phase III trial in men with metastatic castration-resistant prostate cancer and BRCA or ATM mutations.
• On October 25, 2022, the FDA approved Johnson & Johnson’s teclistamab for treating a type of multiple myeloma, giving patients with incurable blood cancer another treatment option.
• In September 2022, BioNTech announced that the first colorectal cancer patient had been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase II clinical trial.
• In August 2022, ALX Oncology initiated the Phase II clinical trial of evorpacept plus Erbitux (cetuximab) and Keytruda (pembrolizumab) in refractory microsatellite stable metastatic colorectal cancer (mCRC) patients. The combination treatment is intended for mCRC patients who have advanced following a minimum of two lines of systemic therapy.
• On April 27, 2022, the FDA granted Breakthrough Therapy Designation to AstraZeneca and Daiichi Sankyo’s Enhertu for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
• On March 17, 2022, the FDA approved the FoundationOne CDx for use as a companion diagnostic to determine which patients with non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions or exon 21 (L858R) substitutions may derive benefit from EGFR TKIs that the agency has greenlighted for this indication.
• On February 21, 2022, the European Commission approved tepotinib (Tepmetko) for use as a single agent in adult patients with advanced Non-small Cell Lung Cancer (NSCLC)
• On October 15, 2021, the FDA approved atezolizumab (Tecentriq) by Genentech, Inc. for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).
• On August 2021, Bristol Myers Squibbs received conditional marketing authorization for Abecma (idecabtagene vicleucel) by the European Commission for treating adult patients with relapsed and refractory multiple myeloma. It is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy.
• On June 2021, the FDA granted product approval to Elekta AB’s Elekta Harmony radiation therapy system to deliver radiotherapy to treat various cancers such as lung, prostate, and breast cancers.
• Thus, owing to such developments in the market, rapid growth will be observed in the cancer therapy market during the forecast period.

Interested in knowing about the recent developments in cancer therapies? Click to get a snapshot of Therapy for Cancer Treatment: https://www.delveinsight.com/report-store/cancer-therapy-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Cancer Therapy Overview
Cancer therapy includes all cancer treatments that aim to kill cancer cells to provide a therapeutic effect, such as chemotherapy, cancer radiation therapy, hormone cancer therapy, and targeted cancer therapy.
As a chronic and debilitating disease, cancer necessitates a multifaceted approach to eradicating malignant cells. Although not all cancers require treatment, the vast majority of them do. Chemotherapy, gene therapy, and immunotherapy are all used in cancer treatment because of the benefits they provide in terms of both curative and palliative effects. These therapies, each with their own set of advantages, are extremely popular cancer treatment options.

Cancer Therapy Market Insights
The global cancer therapy market is studied geographically for North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to amass a significant revenue share in the global cancer therapy market during the forecast period in terms of the largest market share. This can be attributed to the region’s high cancer prevalence and a supportive regulatory environment, among other factors. Furthermore, the region’s high disposable income, sophisticated healthcare infrastructure, and increased awareness of new treatments, combined with extensive insurance coverage for these treatments, are expected to aid in the growth of the cancer therapy market. On the other hand, the European cancer therapy market will challenge North America’s dominance.

Want to gain a better understanding of why North America is dominating the global cancer therapy market? Click to get a snapshot of the Cancer Therapy Market Report: https://www.delveinsight.com/sample-request/cancer-therapy-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Cancer Therapy Market Dynamics
The rise in cancer incidence is one of the key factors driving the cancer therapy market. Another factor contributing to the growth of the cancer therapy market is the increasing popularity of precision medicine in cancer treatment. Furthermore, the advancement of newer technologies, such as RNA sequencing and next-generation sequencing, has significantly driven a more personalized approach, with improvements in detecting predictive and prognostic molecular alterations.
However, potential side-effects of various cancer therapies, such as bone mass loss and the cost of cancer therapies, particularly in low- and middle-income countries, may prove to be challenging factors for cancer therapy market growth.
Nonetheless, the cancer therapy market is recovering due to the development of strategies to transform cancer care, presenting a future outlook for the cancer therapy market during the forecast period of 2023–2030.

Get a sneak peek at the cancer therapy market dynamics @ Cancer Therapy Market Dynamics Analysis

Cancer Therapy Market Assessment
• Coverage: Global
• Study Period: 2021–2030
• Market CAGR: 9.12%
• Key Cancer Therapy Companies. GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others
• Cancer Therapy Market Segmentation
o Market Segmentation By Therapy Type - Chemotherapy, Hormonal Therapy, Targeted Therapy, Radiation Therapy, and Others
o Market Segmentation By Types of Cancer - Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, and Others
o Market Segmentation By End-User - Hospitals, Specialty Clinics, and Others
o Market Segmentation By Geography - North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the cancer therapy market are set to emerge as the trendsetter explore @ Cancer Therapy Companies and Therapies

Table of Contents
1. Report Introduction
2. Executive summary
3. Regulatory and Patent Analysis
4. Key Factors Analysis
5. Porter’s Five Forces Analysis
6. COVID-19 Impact Analysis on Cancer Therapy Market
7. Cancer Therapy Market Layout
8. Global Company Share Analysis – Key 3-5 Companies
9. Cancer Therapy Market Company and Product Profiles
10. Project Approach
11. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Ankit Nigam
DelveInsight Business Research
+1 469-945-7679
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube